Hope or hype the obsession with medical advances and the high cost of false promises /
Saved in:
| 主要作者: | |
|---|---|
| 企業作者: | |
| 其他作者: | |
| 格式: | 電子 電子書 |
| 語言: | 英语 |
| 出版: |
New York :
AMACOM, American Management Association,
c2005.
|
| 主題: | |
| 在線閱讀: | An electronic book accessible through the World Wide Web; click to view |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
書本目錄:
- Can there be too much of a good thing? the hazards of uncritically embracing medical advances
- What's the problem? don't we need lifesaving new treatments?
- Medical innovations and American culture: the call of the sirens
- Why more isn't always better: red herrings, side effects, and superbugs
- Why newer isn't always better: unpleasant surprises, recalls, and learning curves
- Social hazards: what we lose by uncritical use of new treatments
- How things really work: opinion makers and regulators of medical advances
- What will you swallow? how drug companies get you to buy more expensive drugs than you may need
- Making friends, playing monopoly, and dirty tricks: other industry strategies
- Stacking the deck? how to get the "right" answer in clinical research
- "Cancer cured--film at 11:00": the media's role in disseminating medical advances
- Doctors and hospitals: fueling the drive for new and more
- Advocacy groups: Mother Teresa's waiting room
- Holes in the safety net: the FDA and the FTC
- Ineffective. inferior or needlessly costly new drugs
- Medical devices that disappoint
- Ineffective or needlessly extensive surgery
- Weight loss technology: shedding pounds from your waistline or your wallet?
- For doctors: evidence-based medicine
- For insurers and researchers: pay now or pay more later
- For all decision makers: getting value for money
- For government: regulatory approaches to improve the dissemination of medical innovations
- For consumers: shared decision making.
- Can there be too much of a good thing? the hazards of uncritically embracing medical advances
- What's the problem? don't we need lifesaving new treatments?
- Medical innovations and American culture: the call of the sirens
- Why more isn't always better: red herrings, side effects, and superbugs
- Why newer isn't always better: unpleasant surprises, recalls, and learning curves
- Social hazards: what we lose by uncritical use of new treatments
- How things really work: opinion makers and regulators of medical advances
- What will you swallow? how drug companies get you to buy more expensive drugs than you may need
- Making friends, playing monopoly, and dirty tricks: other industry strategies
- Stacking the deck? how to get the "right" answer in clinical research
- "Cancer cured--film at 11:00": the media's role in disseminating medical advances
- Doctors and hospitals: fueling the drive for new and more
- Advocacy groups: Mother Teresa's waiting room
- Holes in the safety net: the FDA and the FTC
- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death
- Ineffective or inferior new drugs
- Medical devices that disappoint
- Ineffective or needlessly extensive surgery
- Weight loss technology: shedding pounds from your waistline or your wallet?
- Crossing the threshold: improving the transition from "experimental" to "standard care"
- For doctors: evidence-based medicine
- For insurers and researchers: pay now or pay more later
- For all decision makers: getting value for money
- For government: regulatory approaches to improve the dissemination of medical innovations
- For consumers: shared decision making.